Cardiac imaging plays an essential role in the diagnosis of HCM, as well as in family screening, treatment decision making, SCD risk stratification, and treatment follow-up in this disease. 3 experts dive into this topic and share their knowledge on multimodality imaging in HCM.
This course consists of 3 episodes. View all episodes, answer the pre- and post-test questions, and start earning CME credits.
Funding for this educational program was provided by an unrestricted educational grant from Bristol Myers Squibb.
This course consists of 3 episodes. View all episodes, answer the pre- and post-test questions, and start earning CME credits.
Understanding hypertrophic cardiomyopathy and recent guidelines - Elena Arbelo, MD, PhD - Barcelona, Spain
Echocardiographic workup for HCM – making the diagnosis and evaluation of cardiac function - Thor Edvardsen, MD, PhD – Oslo, Norway
Role of echocardiography in risk stratification and treatment decision-making - Maurizio Pieroni, MD, PhD - Florence, Italy
For questions regarding this activity, please contact us at info@pace-cme.org.
Describe the role of echocardiography and other imaging techniques in the diagnosis and prognosis of HCM
Recognize echocardiographic patterns across patient scenarios that warrant the application of an HCM-specific therapeutic approach
Examine the role of echocardiography in treatment follow-up and monitoring in patients with HCM
This activity has been designed to meet the educational needs of cardiologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with hypertrophic cardiomyopathy.
This enduring activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC®) for 52 minutes of effective education time.
EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).
Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair: Thor Edvardsen, MD, PhD – Oslo, Norway
Dr. Edvardsen has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Speaker fees: Bristol Myers Squibb.
Faculty: Elena Arbelo, MD, PhD - Barcelona, Spain and Maurizio Pieroni, MD, PhD - Florence, Italy
Dr. Arbelo has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting/Speaker fees from: Boston Scientific, Biosense Webster, Medtronic, Bristol-Myers-Squibb
Dr. Pieroni has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting/Speaker fees from:
Sanofi, Amicus therapeutics, Chiesi Pharma, Pfizer, Bristol Myers Squibb, Cytokinetics.
Reviewers/Content Planners/Authors:
Anja Gerrits, PhD has no relevant relationships to disclose.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and PACE-CME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of PACE-CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Release Date:
Expiration Date:
